Skip to main content
SpringerLink
Log in

Ponatinib: A Review of Its Use in Adults with Chronic Myeloid Leukaemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Oral ponatinib (Iclusig®) is a novel kinase inhibitor structurally designed with a carbon-carbon triple bond to accommodate the T315I mutation in the ABL kinase domain. It has demonstrated inhibitory activity against native BCR-ABL tyrosine kinase and a variety of BCR-ABL mutants, including T315I. Ponatinib is approved for the treatment of adults with T315I-positive chronic-, accelerated- or blast-phase chronic myeloid leukaemia (CML), or Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL) [in the EU and the USA], as well as those with chronic-, accelerated- or blast-phase CML, or Ph+ ALL who are resistant or intolerant to prior tyrosine kinase inhibitor therapy (EU) or for whom no other tyrosine kinase inhibitor therapy is indicated (USA). In a noncomparative, multinational, phase II study, therapy with ponatinib was associated with a major cytogenetic response within the first 12 months in over half of adults with chronic-phase CML and major haematological responses within the first 6 months in at least 50 % of adults with accelerated-phase CML and approximately 34 % of adults with blast-phase CML or Ph+ ALL after a median follow-up duration of 15, 16 and 6 months, respectively. Such benefits were observed regardless of whether the patients were resistant to dasatinib or nilotinib, or had the T315I mutation. Serious adverse reactions have been reported with ponatinib, with vascular occlusion, heart failure and hepatotoxicity prompting the US FDA to issue boxed warnings. Ponatinib is a valuable treatment option for adults with T315I-positive chronic-, accelerated- or blast-phase CML, or Ph+ ALL, as well as those with chronic-, accelerated- or blast-phase CML, or Ph+ ALL who are resistant or intolerant to prior tyrosine kinase inhibitor therapy, but before starting treatment, clinicians need to consider whether the potential benefits of therapy will outweigh the risks.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Cortes J, Goldman JM, Hughes T. Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure. J Natl Compr Cancer Netw. 2012;10(Suppl 3):S1–13.

    CAS  Google Scholar 

  2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia (version 3.2014). 2014. http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf. Accessed 11 April 2014.

  3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: acute lymphoblastic leukemia (version 3.2013). 2013. http://www.nccn.org/professionals/physician_gls/pdf/all.pdf. Accessed 11 April 2014.

  4. O’Hare T, Deininger MWN, Eide CA, et al. Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clin Cancer Res. 2011;17(2):212–21.

    Article  PubMed  Google Scholar 

  5. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–84.

    Article  CAS  PubMed  Google Scholar 

  6. Khorashad JS, de Lavallade H, Apperley JF, et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol. 2008;26(29):4806–13.

    Article  CAS  PubMed  Google Scholar 

  7. Goldman JM. Ponatinib for chronic myeloid leukemia. N Engl J Med. 2012;367(22):2148–9.

    Article  CAS  PubMed  Google Scholar 

  8. Cortes J, Radich J, Mauro MJ. Clinical roundtable monograph: emerging treatment options for TKI-resistant chronic myelogenous leukemia. Clin Adv Hematol Oncol. 2012;10(10 Suppl 19):1–16.

    PubMed  Google Scholar 

  9. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367(22):2075–88.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Ariad Pharmaceuticals Inc. Iclusig® (ponatinib) tablets for oral use: prescribing information; 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203469s007s008lbl.pdf. Accessed 11 April 2014.

  11. O’Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401–12.

    Article  PubMed Central  PubMed  Google Scholar 

  12. European Medicines Agency. Iclusig (ponatinib): summary of product characteristics; 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002695/WC500145646.pdf. Accessed 11 April 2014.

  13. Mauro MJ, Cortes JE, Kantarjian HM, et al. Safety and durability of ponatinib in patients with Philadelphia chromosome-positive (Ph+) leukemia: long-term follow-up of an ongoing phase I study [abstract no. 7063 plus poster]. J Clin Oncol. 2013;31(15 Suppl. 1).

  14. Sonnichsen D, Dorer DJ, Cortes J, et al. Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies. Cancer Chemother Pharmacol. 2013;71(6):1599–607.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. European Medicines Agency. Assessment report: Iclusig (ponatinib); 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002695/WC500145648.pdf. Accessed 11 April 2014.

  16. Narasimhan NI, Dorer DJ, Niland K, et al. Effects of food on the pharmacokinetics of ponatinib in healthy subjects. J Clin Pharm Ther. 2013;38(6):440–4.

    Article  CAS  PubMed  Google Scholar 

  17. Narasimhan NI, Dorer DJ, Niland K, et al. Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects. J Clin Pharmacol. 2013;53(9):974–81.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783–96 (plus supplementary appendix).

  19. Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. Ponatinib in patients (pts) with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL mutation: 2-year follow-up of the PACE trial [abstract no. 650]. Blood. 2013;121(21).

  20. Pinilla-Ibarz J, Cortes JE, Kim D-W, et al. Clinical impact of dose modification on response to ponatinib in patients with chronic phase chronic myeloid leukemia (CP-CML) [abstract no. 4007 plus poster]. Blood. 2013;122(21).

  21. Deininger MW, Shah NP, Cortes JE, et al. Impact of baseline (BL) mutations, including low-level and compound mutations, on ponatinib response and end of treatment (EOT) mutation analysis in patients (Pts) with chronic phase chronic myeloid leukemia (CP-CML) [abstract no. 652]. Blood. 2013;122(21).

  22. Hochhaus A, Kim D-W, Pinilla-Ibarz J, et al. Molecular responses with ponatinib in patients with Philadelphia chromosome positive (Ph+) leukemia: results from the PACE trial [abstract no. 3763 plus poster]. Blood. 2012;120(21).

  23. Mauro MJ, Cortes JE, Kim D-W, et al. Multivariate analyses of the clinical and molecular parameters associated with efficacy and safety in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) treated with ponatinib in the PACE trial [abstract no. 3747 plus poster]. Blood. 2012;120(21).

  24. Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. A pivotal phase 2 trial of ponatinib in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL mutation: 12-month follow-up of the PACE trial [abstract no. 163 plus oral]. Blood. 2012;120(21).

  25. Kantarjian HM, Kim D-W, Pinilla-Ibarz J, et al. Efficacy and safety of ponatinib in patients with accelerated phase or blast phase chronic myeloid leukemia (AP-CML or BP-CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): 12-month follow-up of the PACE trial [abstract no. 915 plus oral]. Blood. 2012;120(21).

  26. Ariad Pharmaceuticals. Ponatinib for chronic myeloid leukemia (CML) evaluation and Ph+ acute lymphoblastic leukemia (ALL) (PACE). [ClinicalTrials.gov identifier NCT01207440]. US National Institutes of Health, ClinicalTrials.gov [online]. 2013. http://clinicaltrials.gov/ct2/show/NCT01207440?term=ponatinib&rank=7. Accessed 11 April 2014.

  27. US Food and Drug Administration. FDA Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug Iclusig; company expected to resume marketing; 2013. http://www.fda.gov/Drugs/DrugSafety/ucm379554.htm. Accessed 11 April 2014.

Download references

Disclosure

The preparation of this review was not supported by any external funding. Sheridan Hoy is a salaried employee of Adis/Springer. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand

    Sheridan M. Hoy

Authors
  1. Sheridan M. Hoy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sheridan M. Hoy.

Additional information

The manuscript was reviewed by: E. Abruzzese, Hematology, S. Eugenio Hospital, Tor Vergata University, Rome, Italy; D.J. DeAngelo, Dana-Faber Cancer Institute, Boston, MA, USA; D.-W. Kim, Division of Hematology, Seoul St. Mary’s Hospital, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hoy, S.M. Ponatinib: A Review of Its Use in Adults with Chronic Myeloid Leukaemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia. Drugs 74, 793–806 (2014). https://doi.org/10.1007/s40265-014-0216-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-014-0216-6

Keywords

Search

Navigation